Evidence map›Paper›PMID 37193183›Full record

ArticleAmerican journal of translational research2023

Diagnostic value of human fecal SDC2 gene in colorectal cancer.

Nanyang Li, Chunmei Li, Xuejun Zhang, Feng Wang, Lian Li, Jingjing Liang, Fengqiang Wang

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Fecal methylated syndecan-2 (Cancer pathogenesis and therapy · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Nanyang LiDepartment of Gastroenterology, Zhangjiakou First Hospital Zhangjiakou 075000, Hebei, China.
Chunmei LiCenter for Disease Control and Prevention Zhangjiakou 075000, Hebei, China.
Xuejun ZhangDepartment of Gastroenterology, Zhangjiakou First Hospital Zhangjiakou 075000, Hebei, China.
Feng WangDepartment of Endoscopy, Zhangjiakou First Hospital Zhangjiakou 075000, Hebei, China.
Lian LiDepartment of Nursing, Zhangjiakou First Hospital Zhangjiakou 075000, Hebei, China.
Jingjing LiangDepartment of Gastroenterology, Zhangjiakou First Hospital Zhangjiakou 075000, Hebei, China.
Fengqiang WangDepartment of Gastroenterology, Zhangjiakou First Hospital Zhangjiakou 075000, Hebei, China.
Zhangjiakou Academy of Agricultural Sciences · CNHebei North University · CNHebei Provincial Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the clinical value of human fecal Syndecan-2 (SDC2) gene methylation in colorectal cancer screening.

methodsThere were 30 patients with colorectal cancer receiving treatment in Zhangjiakou First Hospital from January 2019 to December 2019 collected as the tumor group. There were 30 healthy people determined by a physical examination in 2019 collected as the normal group. The methylation level of fecal SDC2 gene and the level of serum tumor markers including carcinoembryonic antigen (CEA) and Carbohydrate antigen 19-9 (CA19-9) were analyzed. The diagnostic effects of fecal SDC2 methylation and serum tumor markers on colorectal cancer were compared. The area under curve (AUC) of different methods for colorectal cancer diagnosis were evaluated based on the receiver operating characteristic (ROC) curve.

resultsThere was no distinction between the tumor group and the normal group in clinical basic data, including gender, age, and body mass index (P > 0.05), revealing the comparability between the two groups. The level of fecal SDC2 methylation in the tumor group was lower than that in the normal group (P < 0.05). CEA and CA19-9 in the tumor group were higher than those in the normal group (P < 0.05). Among the 30 colorectal cancers, 28 (93.33%) were positive for SDC2 gene methylation, 18 (60%) were positive for serum CEA, and 19 (63.33%) were positive for serum CA19-9. This indicated that the true positive rate of SDC2 gene methylation was higher than that of serum tumor markers (P < 0.05). The AUC of fecal SDC2 gene methylation was 0.981. These were higher than that of serum tumor markers (P < 0.05).

conclusionsFecal SDC2 gene detection has a high sensitivity and specificity for colorectal cancer. It has a very ideal detection effect in detecting colorectal cancer patients in the population.

Indexed as

colorectal cancerdiagnosisFecal SDC2 methylation

Identifiers

PMID37193183
PMCPMC10182478
OpenAlexW4376872808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.